Trial Profile
A study to evaluate whether the FcγR and FGFR4 polymorphisms associated with the pathological complete response to trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Dec 2015
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Cyclophosphamide; Epirubicin; Paclitaxel
- Indications Breast cancer; HER2 positive breast cancer
- Focus Pharmacodynamics
- 12 Dec 2015 New trial record